Eculizumab

ChemicalBook > CAS DataBase List > Eculizumab

Product Name: Eculizumab
CAS No.: 219685-50-4
Chemical Name: Eculizumab
Synonyms: H5G1.1;Alexion;Soliris;Eculizumab;ECULIZUMABUM;Unii-A3ulp0F556;H5G1.1Vhc H5G1.1vlc;Eculizumab USP/EP/BP;Eculizumab, stock solution;Eculizumab (anti-Complement C5)
CBNumber: CB02491712
Formula Weight: 0
MOL File: Mol file

Less

Eculizumab Property

storage temp.: Store at -20°C
CAS DataBase Reference: 219685-50-4

Less

Safety

Hazardous Substances Data: 219685-50-4(Hazardous Substances Data)

Less

Hazard and Precautionary Statements (GHS)

Less

N-Bromosuccinimide Price

American Custom Chemicals Corporation

Product number: API0007496
Product name: ECULIZUMAB
Purity: 95.00%
Packaging: 5MG
Price: $498.98
Updated: 2021/12/16

Biosynth Carbosynth

Product number: BE165588
Product name: Eculizumab
Packaging: 1mg
Price: $500
Updated: 2021/12/16

Biosynth Carbosynth

Product number: BE165588
Product name: Eculizumab
Packaging: 2mg
Price: $700
Updated: 2021/12/16

Biosynth Carbosynth

Product number: BE165588
Product name: Eculizumab
Packaging: 5mg
Price: $1000
Updated: 2021/12/16

DC Chemicals

Product number: 013343
Product name: Eculizumab
Packaging: 002
Price: $1200
Updated: 2021/12/16

Less

Eculizumab Chemical Properties,Usage,Production

Description

Eculizumab, a fully humanized anti-C5 monoclonal antibody, was introduced for treating patients with PNH to reduce hemolysis. It is the first therapy to be approved for this rare and life-threatening form of hemolytic anemia. PNH is a clonal hematopoietic stem-cell disorder that is characterized by the production of abnormal red blood cells (RBCs) with a deficiency of surface proteins that protect the cells against attack by the body’s complement system. Complement-mediated destruction of the susceptible RBCs results in intravascular hemolysis, the primary clinical manifestation in all PNH patients. Previously, patients with PNH have mainly been managed supportively, with red cell transfusions as required, and treatments such as folate and iron supplementation, anticoagulation for thrombotic disease, and the occasional use of steroids during hemolytic crises. Allogenic stem cell transplantation is currently the only curative option for PNH; however, it is associated with significant morbidity and mortality. Eculizumab therapy is aimed at preventing red cell lysis through blockade of complement activation process and the production of the membrane attack complex. Eculizumab specifically binds to the human complement protein C5 with high affinity (IC₅₀ ＝ 2 nM) and inhibits its cleavage to C5a and C5b, which is a key step in the pathway leading to the membrane attack complex C5b-C9.
Eculizumab has been granted orphan drug status from both the FDA and European regulatory agencies.The most serious adverse reaction associated with eculizumab therapy is meningococcal infections. Eculizumab is contraindicated in patients who are not vaccinated against Neisseria meningitidis or who have N. meningitidis infections. The most common adverse reactions with eculizumab include headache (44%), nasopharyngitis (23%), back pain (19%), and nausea (16%).

Originator

Alexion (US)

Uses

Treatment of autoimmune disease such as rheumatoid arthritis, membranous nephritis, lupus nephritis, dermatomyositis, and autoimmune hemolytic anemias.

brand name

Soliris

General Description

Eculizumab (Soliris) is a monoclonal antibodythat binds to the terminal complement protein C5 inRBCs. This blocks the cleavage of C5 and halts the processof complement-mediated cell destruction of the RBCs.Eculizumab has been shown to be effective in treating PNHand in March 2007 was approved by the FDA for treatingPNH.

Clinical Use

Recombinant monoclonal antibody:
Paroxysmal nocturnal haemoglobinuria (PNH)
Atypical haemolytic uraemic syndrome (aHUS)
Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive (MG)

Metabolism

Human antibodies undergo endocytotic digestion in the cells of the reticuloendothelial system. Eculizumab contains only naturally occurring amino acids and has no known active metabolites. Human antibodies are predominately catabolised by lysosomal enzymes to small peptides and amino acids.

Eculizumab Preparation Products And Raw materials

Raw materials

Preparation Products

Less

Eculizumab Suppliers

China 57 United Kingdom 1 United States 2 Global 60

Chembest Research Laboratories Limited

Tel: 021-20908456
Fax: 021-58180499
Email: sales@BioChemBest.com
Country: China
ProdList: 6011
Advantage: 61

Wuhan Fortuna Chemical Co., Ltd

Tel: 027-027-59207852 13308628970
Fax: QQ3130921841
Email: buy@fortunachem.com
Country: China
ProdList: 2892
Advantage: 58

Dalian Meilun Biotech Co., Ltd.

Tel: 0411-62910999 13889544652
Email: sales@meilune.com
Country: China
ProdList: 4659
Advantage: 58

Beijing HuaMeiHuLiBiological Chemical

Tel: 010-56205725
Fax: 010-65763397
Email: waley188@sohu.com
Country: China
ProdList: 12338
Advantage: 58

Sichuan Wei Keqi Biological Technology Co., Ltd.

Tel: 028-81700200 18116577057
Fax: 028-81705658
Email: 3003855609@qq.com
Country: China
ProdList: 7892
Advantage: 56

Taizhou KEDE Chemical Co., Ltd

Tel: 0576-84613060 13093829633
Fax: 0576-84613060
Email: sales@kedechemical.com
Country: China
ProdList: 298
Advantage: 60

Chizhou Kailong Import and Export Trade Co., Ltd.

Tel
Fax: -
Email: xg01_gj@163.com
Country: China
ProdList: 9503
Advantage: 50

Shanghai Lollane Biological Technology Co.,Ltd.

Tel: 021-52996696，15000506266 15000506266
Fax: +86-21-52996696
Country: China
ProdList: 4153
Advantage: 55

Shanghai Hanjing Chemicals Co., Ltd.

Tel: 021-54285032 13641685631
Fax: +86 (21) 5443 7651
Email: gerry.shu@hanjingchemicals.com
Country: China
ProdList: 76
Advantage: 55

Shanghai EFE Biological Technology Co., Ltd.

Tel: 021-65675885 18964387627
Fax: 021-65675885
Email: info@efebio.com
Country: China
ProdList: 9709
Advantage: 58

ShangHai Biochempartner Co.,Ltd

Tel: 17754423994 17754423994
Fax: QQ:2853530913
Email: 2853530910@QQ.com
Country: China
ProdList: 8011
Advantage: 62

Shanghai Rechem science Co., Ltd.

Tel: 21-31433387 15618786686
Fax: QQ:1369748377
Email: sales@rechemscience.com
Country: China
ProdList: 2990
Advantage: 58

Beijing Solarbio Science & Tecnology Co., Ltd.

Tel: 010-50973130 4009686088
Email: 3193328036@qq.com
Country: China
ProdList: 29797
Advantage: 68

Hefei Hirisun Pharmatech Co., Ltd.

Tel: +86-0551-62678551 +86-15056975894
Fax: 0551-62678551
Email: sales@hirisunpharm.com
Country: China
ProdList: 180
Advantage: 55

Wellman Pharmaceutical Group Limited

Tel: 027-027-83778875 15807197853
Fax: 027-83991220
Email: 15807197853@163.com
Country: China
ProdList: 3979
Advantage: 58

Taizhou Crene Biotechnology Co. Ltd.

Tel: 0576-88813233 13396860566
Email: sales@pharm-intermediates.com
Country: China
ProdList: 2013
Advantage: 58

Tianjin Kaifu Pharmaceutical Technology Co., Ltd.

Tel: 18081075745
Email: chemflowtech@sina.com
Country: China
ProdList: 1886
Advantage: 58

Hangzhou Huarong Pharm Co., Ltd.

Tel: 571-86758373 +8613588754946
Fax: 0086-571-81131109
Email: sales@huarongpharm.com
Country: CHINA
ProdList: 3149
Advantage: 58

Dideu Industries Group Limited

Tel: +86-29-89586680 +86-15129568250
Email: 1026@dideu.com
Country: China
ProdList: 28455
Advantage: 58

Hefei Hirisun Pharmatech Co., Ltd

Tel: +8615056975894
Fax: 86-0551-62678551
Email: shawn@hirisunpharm.com
Country: CHINA
ProdList: 9923
Advantage: 58

Baoji Guokang Healthchem co.,ltd

Tel: +8615604608665 15604608665
Email: dominicguo@gk-bio.com
Country: CHINA
ProdList: 9427
Advantage: 58

AFINE CHEMICALS LIMITED

Tel: 0571-85134551 18958018566;
Fax: 008657185134895
Email: info@afinechem.com
Country: China
ProdList: 15377
Advantage: 58

Career Henan Chemica Co

Tel: +86-0371-86658258 15093356674;
Fax: 0371-86658258
Email: laboratory@coreychem.com
Country: China
ProdList: 30255
Advantage: 58

DC Chemicals

Tel: 021-58447131 13564518121
Email: sales@dcchemicals.com
Country: China
ProdList: 9414
Advantage: 58

Changzhou Chenhong Biotechnology Co., Ltd.

Tel: 0519-85788828 13775037613
Email: sales@chemrenpharm.com
Country: China
ProdList: 3553
Advantage: 58

Wuhan Dingtong Pharmaceutical Co., Ltd

Tel: 027-027-59207795 18327179646
Fax: 027-59207795
Email: 18327179646@163.com
Country: China
ProdList: 1987
Advantage: 58

Wuhan Wiseman Bioengineering Co.,Ltd

Tel: 027-59506022 13419526507
Fax: 027-59506022
Email: 13419526507@163.com
Country: China
ProdList: 2932
Advantage: 58

Wuhan Chemstan Biotechnology Co., Ltd.

Tel: 027-65317797 15926423062
Fax: QQ：422450190
Email: 422450190@qq.com
Country: China
ProdList: 10055
Advantage: 58

Hubei Zhongshan Medical Technology Co., Ltd

Tel: 027-61907345 13397111514
Fax: 3443707954
Email: w13397111514@163.com
Country: China
ProdList: 1011
Advantage: 58

Shanghai Minkai Biological Technology Co., Ltd

Tel: 021-52919136 17315815539
Email: 2804155403@qq.com
Country: China
ProdList: 169
Advantage: 58

Abmole Bioscience Inc.

Tel: 021-50967598 02150967598
Email: sales@abmole.cn
Country: China
ProdList: 4495
Advantage: 58

Nantong Hi-Future Biotechnology Co., Ltd

Tel: 18051384581
Email: sales@chemhifuture.com
Country: China
ProdList: 3063
Advantage: 58

SUZHOU MAYSIXTH TRADING CO.LTD

Tel: 17715515539
Email: zhangxin@maysixth.cn
Country: China
ProdList: 58
Advantage: 58

Hubei Kele Fine Chemical Co., Ltd

Tel: 027-59101668 19945030958
Fax: 027-59101668
Email: 2881924765@qq.com
Country: China
ProdList: 7977
Advantage: 58

Hubei wei shi reagent group ltd., company

Tel: 186-27096350 18627096350
Fax: 027-59379337
Email: 2853877630@qq.com
Country: China
ProdList: 2646
Advantage: 58

Jiangxi ravel Biotechnology Co.,Ltd

Tel: 400-880-2824 15608648206
Email: 1987516016@qq.com
Country: China
ProdList: 2608
Advantage: 58

Jiangxi ravel Biotechnology Co.,Ltd

Tel: 185-0276-2003 18502762003;
Email: 435918333@qq.com
Country: China
ProdList: 2243
Advantage: 58

Wuhan Yingnuo Pharmaceutical Technology Co., Ltd.

Tel: +86-027-59232304 15387063101
Email: 2881924050@qq.com
Country: China
ProdList: 9892
Advantage: 58

Hubei Weideli Chemical Reagent Co.，Ltd.

Tel: 027-02759222918 13385289472
Email: Z13385289472@163.com
Country: China
ProdList: 4606
Advantage: 58

TargetMol Chemicals Inc.

Tel: 4008200310
Email: marketing@tsbiochem.com
Country: China
ProdList: 24023
Advantage: 58

Hubei wei shi reagent group ltd., company

Tel: 027-59105166 13125137732
Email: 2853863890@qq.com
Country: China
ProdList: 2941
Advantage: 58

Hubei Wanye Zhongcheng Chemical Reagent Co., Ltd.

Tel: 18671296875
Email: 1205035102@qq.com
Country: China
ProdList: 4069
Advantage: 58

Hubei Enxing Biotechnology Co., Ltd

Tel: 16621771607
Email: exbio_tech@163.com
Country: China
ProdList: 8352
Advantage: 58

AntibodySystem

Tel: 027-65279366 18162686757
Email: biolab-reagents@atagenix.com
Country: China
ProdList: 9800
Advantage: 58

Wuhan Jingkangen Biomedical Technology Co., Ltd

Tel: 13720134139 13720134139
Email: orders@jknbiochem.com
Country: China
ProdList: 5223
Advantage: 58

Wuhan Acumen Bio-Technology Co.,ltd

Tel: 027-027-16602739303 16602739303
Email: 673003916@qq.com
Country: China
ProdList: 2887
Advantage: 58

Shanghai Aladdin Biochemical Technology Co.,Ltd.

Tel: +86-18521732826
Email: market@aladdin-e.com
Country: China
ProdList: 48467
Advantage: 58

Hunan Revel Biotechnology Co. , Ltd.

Tel: 19359985961 19359985961
Email: 2430503320@qq.com
Country: China
ProdList: 1065
Advantage: 58

Shanghai jerryxing Biomedical Technology Co., Ltd

Tel: 17721492509
Email: 643638326@qq.com
Country: China
ProdList: 5347
Advantage: 58

Changsha Fuzhen Biotechnology Co.，LTD

Tel: 0731-18670069958 18670069958
Email: 184792226@qq.com
Country: China
ProdList: 3007
Advantage: 58

Less

View Lastest Price from Eculizumab manufacturers

Hangzhou Huarong Pharm Co., Ltd.

Product: Eculizumab 219685-50-4
Price: US $0.00-0.00/g
Min. Order: 100mg
Purity: 99%
Supply Ability: 100KG
Release date: 2021-09-15

Dideu Industries Group Limited

Product: Eculizumab 219685-50-4
Price: US $1.10/g
Min. Order: 1g
Purity: 99.9%
Supply Ability: 100 Tons min
Release date: 2021-08-17

Career Henan Chemica Co

Product: Eculizumab 219685-50-4
Price: US $1.80/KG
Min. Order: 1g
Purity: 98%
Supply Ability: 1KG/10KG/100KG
Release date: 2020-11-02

219685-50-4, EculizumabRelated Search:

Adalimumab Ustekinumab Nivolumab Bevacizumab Daratumumab OMALIZUMAB Lambrolizumab Dulaglutide Infliximab Rituximab palivizumab Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer Atezolizumab Denosumab CETUXIMAB Evolocumab Ramucirumab ipilimumab

Alexion

Eculizumab

H5G1.1

H5G1.1Vhc H5G1.1vlc

Soliris

Unii-A3ulp0F556

ECULIZUMABUM

IMMunoglobulin,anti-(huMan coMpleMent C5 a-chain) (huMan-Mouse Monoclonal 5G1.1 heavy chain), disulfide withhuMan-Mouse Monoclonal 5G1.1 light chain, diMer (9CI)

Eculizumab, stock solution

ECULIZUMAB COMPLEMENT C5 219685-50-4

Eculizumab USP/EP/BP

Research Grade Eculizumab(DHB90002)

inhibit,C5a,C5b,haemolysis,membrane attack complex,humanized monoclonal antibody,Anti-Human C5, Humanized Antibody,Complement System,Eculizumab,complement C5,Inhibitor,MAC

Eculizumab (anti-Complement C5)

219685-50-4